$1.20
+0.05 (+4.35%)
Open$1.22
Previous Close$1.15
Day High$1.22
Day Low$1.15
52W High$17.78
52W Low$10.43
Volume—
Avg Volume597.7K
Market Cap5.89M
P/E Ratio53.47
EPS$0.24
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,279.2% upside
Current
$1.20
$1.20
Target
$16.55
$16.55
$10.07
$16.55 avg
$19.24
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 953.7K | 857.2K | 883.5K |
| Net Income | 90.7K | 81.5K | 110.3K |
| Profit Margin | 9.5% | 9.5% | 12.5% |
| EBITDA | 169.7K | 158.3K | 158.7K |
| Free Cash Flow | 104.6K | 58.4K | 79.5K |
| Rev Growth | +23.3% | +22.6% | +12.8% |
| Debt/Equity | 0.69 | 0.48 | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |